alexa The Inflammasome As Future Therapeutic Target: Development Of Inflammasome Challenge Tests
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

M R Dillingh
Posters: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.018
Abstract
Inflammasomes are multiprotein complexes inducing pro-inflammatory cytokine production in response to infection and tissue injury. The end product of inflammasome activity is caspase-1-induced release of effector molecules such as IL-1 β and IL-18 from immune cells. Despite the common outcome, the variety of triggers that initiate inflammasome activity is large, and moreover eight different inflammasome subclasses have been described. The inflammasome is a potential therapeutic target for chronic inflammatory diseases such as chronic kidney disease and atherosclerosis. To test the effects of future inflammasome- targeted therapies, an ?inflammasome bioassay? is highly warranted. The inflammasome?s capacity to sense widely divergent ligands, and the diversity in inflammasome subclasses, indicates that a single bioassay may not be sufficient to assess potential inflammasome-modulating effects of new compounds. Therefore, we developed a set of bioassays inducing inflammasome activity, so-called ?inflammasome challenges?. Variables that were explored included matrix/cells (whole blood, PBMCs, THP1), triggers, incubation time (3-24 hours), dose-response relationship, single trigger versus immune cell priming followed by a second trigger, and inflammasome end products (IL-1β, IL-18). We successfully developed a set of inflammasome challenges, comprising inflammasome activation by LPS alone and by different triggers after LPS priming (extracellular ATP, aluminium hydroxide, cholesterol crystals, oligomeric β-amyloid). The short-term LPS inflammasome challenge was demonstrated to be sensitive to modulation of inflammasome activity, as assessed with a direct caspase-1 inhibitor. These inflammasome challenges can be applied in translational drug development as readout measures for inflammasome inhibition, and moreover will provide mechanistic insight in regulation of inflammasome activity.
Biography
Marlous Dillingh has a background in biomedical sciences. She is currently in training as a clinical pharmacologist at the Centre for Human Drug Research, Leiden, The Netherlands. Her main expertise is the integration of inflammation/immunology and pharmacology, applied in early phase clinical drug development, which is the focus of her PhD education.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords